US commission warns China seeks control of the entire global pharmaceutical supply chain
The US National Security Commission on Emerging Biotechnology (NSCEB) warned in a report that China seeks to expand its control over the entire pharmaceutical chain, from manufacturing to the discovery and commercialization of treatments. The document says pharmaceutical companies operating in the US have increased their deals with Chinese biotech firms, which the commission says transfers capital and knowledge. It also mentions a Chinese sectoral plan with targets to 2030 and a proposal to control exports of biopharmaceutical technologies.
In 45 seconds
- The NSCEB warns China is advancing across the entire pharmaceutical chain, including intellectual property and patented therapies
- The report examined 57 deals between 15 large pharmaceutical companies operating in the US and 42 Chinese biotech firms between January 2023 and October 2026
- According to the document, China published a sectoral plan in September 2026 with targets to 2030 and more than 300 priority technologies
IASummary generated by artificial intelligence from a story by Infobae. It may contain errors: the original source prevails.




Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.